Enzymatica AB (publ) (ENZY.ST)
SEK 3.48
(2.35%)
SEK 3.48
(2.35%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 49.3 Million SEK | 2.46% |
| 2022 | 48.12 Million SEK | 50.06% |
| 2021 | 32.06 Million SEK | -42.09% |
| 2020 | 55.38 Million SEK | 94.26% |
| 2019 | 28.5 Million SEK | 11.74% |
| 2018 | 25.51 Million SEK | 10.33% |
| 2017 | 23.12 Million SEK | 12.26% |
| 2016 | 20.59 Million SEK | -5.8% |
| 2015 | 21.86 Million SEK | 124.44% |
| 2014 | 9.74 Million SEK | -5.32% |
| 2013 | 10.29 Million SEK | 424.2% |
| 2012 | 1.96 Million SEK | 47.59% |
| 2011 | 1.33 Million SEK | 0.0% |
| 2009 | 2.12 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 45.91 Million SEK | -13.59% |
| 2024 Q1 | 53.14 Million SEK | 7.78% |
| 2023 Q2 | 42.25 Million SEK | 5.19% |
| 2023 Q1 | 40.17 Million SEK | -16.52% |
| 2023 FY | 49.3 Million SEK | 2.46% |
| 2023 Q4 | 49.3 Million SEK | 3.18% |
| 2023 Q3 | 47.78 Million SEK | 13.08% |
| 2022 Q4 | 48.12 Million SEK | -74.19% |
| 2022 Q1 | 29.25 Million SEK | -8.79% |
| 2022 FY | 48.12 Million SEK | 50.06% |
| 2022 Q3 | 186.46 Million SEK | 401.89% |
| 2022 Q2 | 37.15 Million SEK | 27.02% |
| 2021 FY | 32.06 Million SEK | -42.09% |
| 2021 Q4 | 32.06 Million SEK | -17.63% |
| 2021 Q2 | 44.09 Million SEK | -7.13% |
| 2021 Q1 | 47.48 Million SEK | -14.26% |
| 2021 Q3 | 38.93 Million SEK | -11.72% |
| 2020 Q2 | 38.21 Million SEK | -8.44% |
| 2020 Q3 | 42.65 Million SEK | 11.6% |
| 2020 Q4 | 55.38 Million SEK | 29.84% |
| 2020 FY | 55.38 Million SEK | 94.26% |
| 2020 Q1 | 41.73 Million SEK | 46.41% |
| 2019 FY | 28.5 Million SEK | 11.74% |
| 2019 Q1 | 21.54 Million SEK | -15.54% |
| 2019 Q2 | 18.07 Million SEK | -16.1% |
| 2019 Q3 | 23.48 Million SEK | 29.93% |
| 2019 Q4 | 28.5 Million SEK | 21.37% |
| 2018 Q1 | 23.15 Million SEK | 0.11% |
| 2018 FY | 25.51 Million SEK | 10.33% |
| 2018 Q3 | 51.31 Million SEK | 72.02% |
| 2018 Q2 | 29.83 Million SEK | 28.86% |
| 2018 Q4 | 25.51 Million SEK | -50.28% |
| 2017 Q3 | 22.23 Million SEK | 29.92% |
| 2017 Q1 | 17.11 Million SEK | -16.89% |
| 2017 Q4 | 23.12 Million SEK | 4.02% |
| 2017 FY | 23.12 Million SEK | 12.26% |
| 2017 Q2 | 17.11 Million SEK | -0.05% |
| 2016 Q4 | 20.59 Million SEK | -11.51% |
| 2016 FY | 20.59 Million SEK | -5.8% |
| 2016 Q2 | 19.61 Million SEK | -26.89% |
| 2016 Q3 | 23.27 Million SEK | 18.7% |
| 2016 Q1 | 26.82 Million SEK | 22.67% |
| 2015 Q3 | 10.46 Million SEK | -25.27% |
| 2015 Q2 | 14 Million SEK | 97.28% |
| 2015 Q4 | 21.86 Million SEK | 108.87% |
| 2015 Q1 | 7.1 Million SEK | -27.12% |
| 2015 FY | 21.86 Million SEK | 124.44% |
| 2014 Q2 | 10.11 Million SEK | -0.55% |
| 2014 Q4 | 9.74 Million SEK | 7.43% |
| 2014 Q3 | 9.06 Million SEK | -10.31% |
| 2014 FY | 9.74 Million SEK | -5.32% |
| 2014 Q1 | 10.16 Million SEK | -1.19% |
| 2013 Q4 | 10.29 Million SEK | 65.86% |
| 2013 Q3 | 6.2 Million SEK | 122.29% |
| 2013 FY | 10.29 Million SEK | 424.2% |
| 2013 Q1 | 2.93 Million SEK | 49.72% |
| 2013 Q2 | 2.79 Million SEK | -5.04% |
| 2012 Q2 | 2.02 Million SEK | 18.27% |
| 2012 Q3 | 2.56 Million SEK | 26.36% |
| 2012 Q1 | 1.71 Million SEK | 0.0% |
| 2012 Q4 | 1.96 Million SEK | -23.41% |
| 2012 FY | 1.96 Million SEK | 47.59% |
| 2011 FY | 1.33 Million SEK | 0.0% |
| 2011 Q3 | 1.48 Million SEK | -2.03% |
| 2011 Q2 | 1.51 Million SEK | 0.0% |
| 2009 FY | 2.12 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcuCort AB | 10.97 Million SEK | -349.221% |
| AlzeCure Pharma AB (publ) | 8.22 Million SEK | -499.271% |
| BioGaia AB (publ) | 302.84 Million SEK | 83.72% |
| Enorama Pharma AB (publ) | 14.84 Million SEK | -232.067% |
| Gabather AB (publ) | 6.87 Million SEK | -616.807% |
| Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | -54.136% |
| Moberg Pharma AB (publ) | 24 Million SEK | -105.365% |
| Nanexa AB (publ) | 36.42 Million SEK | -35.345% |
| Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | -26.565% |
| ODI Pharma AB | 10.05 Million SEK | -390.193% |
| Orexo AB (publ) | 727.7 Million SEK | 93.225% |
| Probi AB (publ) | 181.31 Million SEK | 72.809% |
| Swedencare AB (publ) | 2.31 Billion SEK | 97.871% |
| Swedish Orphan Biovitrum AB (publ) | 40.16 Billion SEK | 99.877% |
| Toleranzia AB | 6.9 Million SEK | -613.591% |
| Vivesto AB | 30.45 Million SEK | -61.901% |